Synonyms: MMV688978 | Ridaura® | SK&F-39162 | SK-39162
auranofin is an approved drug (FDA (1985))
Compound class:
Synthetic organic
Comment: Auranofin is a gold-containing complex, antirheumatic agent. It demonstrates potent antibacterial activity in vitro against Gram-positive bacteria and both replicating and nonreplicating Mycobacterium tuberculosis [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Auranofin is a gold-containing medicine used for the management of rheumatoid arthritis in patients who do not respond to or are intolerant of other medicines. |
Mechanism Of Action and Pharmacodynamic Effects |
Drug treatment decreases levels of rheumatoid factors and immunoglobulins, potentially via inhibition of the selenoenzyme, thioredoxin reductase [1] which has been shown to suppress the pro-inflammatory NLRP3/interleukin-1β pathway. Auranofin is a potent inhibitor of bacterial thioredoxin reductase, disrupting the redox balance and resulting in bacterial cell death [2]. |
External links |
For extended ADME data see the following: Drugs.com |